000 04488nam a22006135i 4500
001 978-3-031-35155-6
003 DE-He213
005 20240207153610.0
007 cr nn 008mamaa
008 230808s2023 sz | s |||| 0|eng d
020 _a9783031351556
_9978-3-031-35155-6
050 4 _aQK
072 7 _aPST
_2bicssc
072 7 _aSCI011000
_2bisacsh
072 7 _aPST
_2thema
082 0 4 _a580
_223
100 1 _aRoss, Ivan A.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
245 1 0 _aPlant-Based Therapeutics, Volume 1
_h[electronic resource] :
_bCannabis sativa /
_cby Ivan A. Ross.
250 _a1st ed. 2023.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2023.
300 _aXXI, 657 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
500 _aAcceso multiusuario
505 0 _aChapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.
520 _aBy examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions. .
541 _fUABC ;
_cPerpetuidad
650 0 _aBotany.
650 0 _aAlternative medicine.
650 0 _aPharmacology.
650 0 _aMedicinal chemistry.
650 0 _aPhysiology.
650 0 _aAgriculture.
650 1 4 _aPlant Science.
650 2 4 _aComplementary and Alternative Medicine.
650 2 4 _aPharmacology.
650 2 4 _aMedicinal Chemistry.
650 2 4 _aPhysiology.
650 2 4 _aAgriculture.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031351549
776 0 8 _iPrinted edition:
_z9783031351563
776 0 8 _iPrinted edition:
_z9783031351570
856 4 0 _zLibro electrónico
_uhttp://libcon.rec.uabc.mx:2048/login?url=https://doi.org/10.1007/978-3-031-35155-6
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c261716
_d261715